bristar immunotech
Better T Cell Therapy
Better Patient Outcomes
bristar immunotech
IN CHINA
HELPING PATIENTS
GLOBALLY
bristar immunotech
PIONEERING CELLULAR
IMMUNOTHERAPIES
bristar immunotech
PATIENTS
FIRST
News
- 2026-04-20
AACR Annual Meeting | BriSTAR Immunotech's Presents Clinical Progress of GPC3-Targeted STAR-T Cell Therapy at AACR 2026
Recently, the 2026 Annual Meeting of the American Association for Cancer Research (AACR), a globally influential academic event in oncology, was successfully held in San Diego, California, USA. Following the presentation of LILRB4-targeted STAR-T research data at AACR 2023, Sinocelltech once again made a major appearance on this top international academic stage. This
- 2025-08-29
Nature Medicine Publishes a Breakthrough! Experts highly praise
A major step forward for off-the-shelf cell therapy in autoimmunity. Prof. Huji Xu, Prof. Xin Lin, and BriSTAR Immunotech are breaking new ground with YTS109, a hypoimmune allogeneic T cell product. Published in Nature Medicine:
- 2025-08-28
Landmark Study Published in Nature Medicine: BriSTAR Immunotech’s Allogeneic STAR-T Breaks New Ground in Refractory Lupus Nephritis Treatment
On August 27, 2025, a groundbreaking study by BriSTAR Immunotech in collaboration with the team led by Professor Huji Xu and Professor Xin Lin , was published in the top international journal Nature Medicine (Impact Factor: 58.7).
About us
BriSTAR Immunotech was founded in 2018 by globally renowned immunologists, and develops high-efficacy engineered T cell immunotherapy products for cancer and autoimmune diseases via proprietary STAR-T and off-the-shelf STAR-T platforms. The company has obtained 2 China IND clinical approvals and 1 FDA orphan drug designation; it has filed nearly 100 invention patents globally and been granted more than 10 Chinese invention patents and PCT patents. We will continue to accelerate the clinical translation and industrialization of our products, and drive the industrial upgrading of cellular therapy.
-
2018
Established In
-
60+
Employees
-
2000m²
37,600 sq.ft. R&D center
-
8+
Important Publications
Platform
Technology
Manufacturing
Pioneering Technology Platform
STAR-T & TCR-T
Technology
Pioneering Technology Platform
STAR-T & Off-the-shelf STAR-T
In vivo STAR-T
Manufacturing
Pipeline
The company is actively promoting the development of universal cell therapy products, treatments for autoimmune diseases, therapies for solid tumors, and new targets for hematologic tumor products.
READ MOREStay In Touch With BriSTAR Immunotech
Send our team your questions | Sign up to receive news updates